Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Phase 1 Trial to Assess Safety and Immunogenicity of Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)

12 de noviembre de 2026 actualizado por: Immorna Biotherapeutics, Inc.

Randomized, Double-Blinded, Placebo-Controlled Phase 1 Clinical Trial to Assess the Safety and Immunogenicity of Two Doses of Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105) in Healthy Participants

Herpes zoster is caused by reactivation of varicella zoster virus. This is a Phase 1 clinical trial to evaluate the safety and immunogenicity of self-replicating RNA (srRNA) herpes zoster vaccine JCXH-105. Eligible participants will receive 2 doses of study vaccine/placebo at planned dose levels and follow scheduled safety and immunogenicity follow-up visits. The goal of this study is to assess the safety profile and immune response induced by JCXH-105.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

72

Fase

  • Fase 1

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

40 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • (1) Gender: Male or female; (2) Age: ≥ 40 years of age at screening. (3) Status: Healthy participants. (4) Subject agrees not to receive any other herpes zoster vaccine while participating in this study.

    (5) All Laboratory values required for screening prior to study enrollment are within normal limits or abnormal without clinical significance as judged by the investigator.

    (6) Female participants must meet the following criteria:

    • Surgically sterile or postmenopausal for ≥ 2 years, or women of childbearing potential (premenopausal or postmenopausal for < 2 years) who have a negative pregnancy test and are willing to use effective contraception from the first administration of investigational vaccine/placebo to 12 months after the full-course vaccination.

    • Agree not to breastfeed from the first administration of investigational vaccine/placebo to at least 3 months after the full-course vaccination.

      (7) Male participants should meet the following criteria: agree to use effective contraception and not to donate sperms from the first administration of investigational vaccine/placebo to 12 months after the full-course vaccination.

      (8) Able to fully understand and voluntarily sign the informed consent form.

Exclusion Criteria:

  • (1) Participants who have a history of herpes zoster or are currently diagnosed with herpes zoster, or have a history of chickenpox, or a history of close contact with chickenpox/herpes zoster patients within 30 days before enrollment.

    (2) History of chickenpox or herpes zoster vaccination. (3) Hypersensitivity to any component of the investigational vaccine/placebo, or any previous serious reaction to vaccination, or a history of serious allergic disease.

    (4) Fever within 3 days prior to enrollment, acute illness or acute exacerbation of chronic illness within 7 days prior to enrollment, or taking antipyretic, analgesic, and anti-allergic drugs within 3 days prior to enrollment.

    (5) History of significant cardiac disease, or myocarditis or pericarditis. (6) At present, participants with severe liver and kidney diseases, spleen dysfunction or asplenia, hypertension that cannot be controlled by drugs, diabetes with serious complications and other chronic diseases are currently suffering.

    (7) Use of whole blood, blood products, or immunoglobulins within 3 months prior to vaccination or planned use during the study.

    (8) Has received any inactive vaccine within 14 days prior to the first dose of vaccine.

    (9) Received the following within 28 days prior to the first dose of vaccine: Any live/mRNA vaccine; Immunomodulators or immunosuppressive drugs; Granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor; Receiving systemic corticosteroids for 3 or more consecutive days. (Note: Study participants are permitted to receive long-term systemic prednisone at a dose ≤10 mg/day, or systemic corticosteroids equivalent to prednisone. Topical medications such as ointments, eye drops, inhalants or nasal sprays are allowed, provided that the topical medications should not exceed the recommended dose in the instructions and there are no signs of systemic exposure.) (10) Have confirmed or suspected immunosuppression, immunodeficiency, or autoimmune disease.

    (11) Positive screening test for HIV antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies.

    (12) Known history of active or latent tuberculosis (Mycobacterium tuberculosis).

    (13) Axillary temperature > 37.0 °C at enrollment. (14) Participation in another drug, device, or other vaccine clinical trial within 30 days prior to the first dose of investigational vaccine/placebo or planned participation during the study period.

    (15) Participants with dermatologic condition that could affect local solicited adverse reaction assessments (e.g., tattoos, psoriasis, patches affecting skin over the deltoid area).

    (16) Participants with contraindications to IM injection. (17) The investigator considers that there are other situations unsuitable for participating in this study, including but not limited to failure to participate in follow-up according to the study protocol.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Low-dose JCXH-105

Participants receive low dose of JCXH-105

Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)

Comparador de placebos: Low-dose placebo

Participants receive low dose of placebo

Placebo (sodium chloride injection) as control

Experimental: Medium-dose JCXH-105

Participants receive medium dose of JCXH-105

Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)

Comparador de placebos: Medium-dose placebo

Participants receive medium dose of placebo

Placebo (sodium chloride injection) as control

Experimental: High-dose JCXH-105

Participants receive high dose of JCXH-105

Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)

Comparador de placebos: High-dose placebo

Participants receive high dose of placebo

Placebo (sodium chloride injection) as control

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Serious adverse events (SAEs)
Periodo de tiempo: From Day 1 post- administration through 360 days after the full-course vaccination

Including frequency, severity, duration, and relationship to the investigational vaccine/placebo

From Day 1 post- administration through 360 days after the full-course vaccination
Solicited local injection site adverse events
Periodo de tiempo: Within 14 days after each dose of investigational vaccine/placebo

Including frequency, severity, duration, and relationship to the investigational vaccine/placebo

Within 14 days after each dose of investigational vaccine/placebo
Solicited systemic adverse events
Periodo de tiempo: Within 14 days after each dose of the investigational vaccine/placebo

Including frequency, severity, duration, and relationship to the investigational vaccine/placebo

Within 14 days after each dose of the investigational vaccine/placebo
Unsolicited AEs
Periodo de tiempo: Within 30 days after each dose of the investigational vaccine/placebo

Including frequency, severity, duration, and relationship to the investigational vaccine/placebo

Within 30 days after each dose of the investigational vaccine/placebo
Laboratory parameters
Periodo de tiempo: On the third day after each dose of the investigational vaccine/placebo

Clinically significant abnormal changes of laboratory parameters compared with pre-vaccination

On the third day after each dose of the investigational vaccine/placebo
Adverse events of special interest (AESIs)
Periodo de tiempo: From Day 1 post administration through 360 days after the full-course vaccination

Including frequency, severity, duration, and relationship to the investigational vaccine/placebo

From Day 1 post administration through 360 days after the full-course vaccination

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de noviembre de 2026

Finalización primaria (Estimado)

1 de marzo de 2028

Finalización del estudio (Estimado)

1 de marzo de 2028

Fechas de registro del estudio

Enviado por primera vez

12 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Publicado por primera vez (Actual)

18 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • JCXH-105-002

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir